GFAP and myeloid sarcoma: Do the levels of serum GFAP (and hence the degree of astrocytic damage) found in patients with ‘atypical’ presentations of ON, such as ‘CRION’ and ‘RION’ pattern ON, resemble MS or NMO, or are they distinct from both?